CKD Pharm Concentrates On Novel Anticancer Drugs

South Korean drugmaker Chong Kun Dang Pharmaceutical (CKD Pharm) wants to develop more original pharmaceuticals, focusing on arguably the most lucrative therapeutic area, oncology. The company will increase the amount it spends on R&D and will continue to invest in its sales and marketing capabilities. Given the increasing strength of generic rivals and the erosion of its active pharmaceutical ingredient (API) business by low-cost competitors, BMI believes the strategy is a sound

To read the full article, please take a trial.